Name
Proteins
Accession Number
DBCAT000020
Description

Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.

Drugs
DrugDrug Description
LepirudinA protein-based direct thrombin inhibitor used as an anticoagulant in patients with heparin-induced thrombocytopenia.
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Dornase alfaA synthetic form of human deoxyribonuclease I used to break down extracellular DNA in the lungs, a major source of mucous viscosity in cystic fibrosis.
Denileukin diftitoxA recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
LeuprolideA peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.
Peginterferon alfa-2aA modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
Interferon alfa-n1A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
Darbepoetin alfaA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
ErythropoietinA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
Salmon calcitoninA synthetic peptide form of calcitonin used to inhibit bone resorption in the treatment of hypercalcemia, osteoporosis, and Paget's disease.
Interferon alfa-n3A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus.
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
SargramostimA modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Peginterferon alfa-2bA purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers.
Antihemophilic factor, human recombinantA form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).
Gramicidin DA bactericidal antibiotic used in the treatment of dermatological and ophthalmic infections.
Human immunoglobulin GA purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
Interferon gamma-1bA form of recombinant human interferon used to treat infections associated with chronic granulomatous disease and to slow the progression of severe malignant osteopetrosis.
DesmopressinA synthetic analog of vasopressin used to reduce renal excretion of water in central diabetes insipidus and nocturia.
Coagulation factor VIIa Recombinant HumanA form of recombinant human coagulation Factor VII used to treat hemophilia A and B.
PaliferminA form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy.
GlucagonA form of recombinant glucagon used to treat hypoglycemia in diabetes mellitus and as a part of gastrointestinal imaging procedures.
AldesleukinA recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
Botulinum toxin type BA purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea.
OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
Albumin humanA purified form of human serum albumin used to replace lost albumin in patients with hypoalbuminemia, to treat hypovolemia and ascites, and as a part of some diagnostic imaging kits.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
FollitropinA form of recombinant human follicle stimulating hormone used to stimulate follicle development in women with primary ovarian hypogonadism and in men with hypogonadotropic hypogonadism.
VasopressinA peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy.
Interferon beta-1bA form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.
Insulin porkA purified form of porcine insulin used to control hyperglycemia in diabetes mellitus.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
MuromonabA monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
TositumomabA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Botulinum toxin type AA purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Capromab pendetideA monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Antithymocyte immunoglobulin (rabbit)A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
FilgrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
Agalsidase betaA recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
EnfuvirtideAn HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
Technetium Tc-99m arcitumomabFor imaging colorectal tumors
PentagastrinA gastrin-like molecule used as a diagnostic aid for the evaluation of gastric acid secretory function, gastric hypersecretion, and Zollinger-Ellison tumors.
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
MecaserminA recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
Insulin glulisineA short-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus.
GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
AfamelanotideAn injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP).
PexelizumabFor the treatment of inflammation during cardiac surgery.
AfelimomabInvestigated for use/treatment in sepsis and septicemia.
EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
OregovomabInvestigated for use/treatment in ovarian cancer.
IGN311Intended for the treatment of various forms of cancer.
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
CR002Investigated for use/treatment in nephropathy.
RozrolimupabInvestigated for use/treatment in thrombocytopenia.
Hepatitis B immune globulinAn injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
ObiltoxaximabA monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
XTL-001Investigated for use/treatment in hepatitis (viral, B).
NAV 1800Investigated for use/treatment in colorectal cancer and solid tumors.
BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
AMG 108Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
IratumumabInvestigated for use/treatment in lymphoma (unspecified).
EnokizumabInvestigated for use/treatment in asthma.
RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
FarletuzumabInvestigated for use/treatment in ovarian cancer.
VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
TNX-901Investigated for use/treatment in allergic reaction.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
RI 624Investigated for use/treatment in pain (acute or chronic).
MYO-029Investigated for use/treatment in muscular dystrophy.
LeronlimabA humanized monoclonal antibody being investigated
Glembatumumab vedotinInvestigated for use/treatment in melanoma.
OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
IPH 2101Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
TB-402Investigated for use/treatment in atrial fibrillation and thrombosis.
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
EldelumabInvestigated for use/treatment in ulcerative colitis.
LumiliximabInvestigated for use/treatment in asthma and leukemia (lymphoid).
CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
NimotuzumabAn EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
ClenoliximabInvestigated for use/treatment in rheumatoid arthritis.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
BIIB015Investigated for use/treatment in solid tumors.
MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
AVE9633Investigated for use/treatment in leukemia (myeloid).
CarotuximabInvestigated for use/treatment in solid tumors.
XmAb 2513Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
TeprotumumabA fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease.
LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
LerdelimumabInvestigated for use/treatment in glaucoma and cataracts.
LexatumumabInvestigated for use/treatment in cancer/tumors (unspecified).
ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
TeplizumabA humanized IgG1κ Fc-nonbinding anti-CD3 monoclonal antibody currently under development as an immune therapy to prolong progression to type 1 diabetes in high-risk patients.
CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
MepolizumabA fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
LiraglutideA GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
AprotininA serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
BelimumabA B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus.
RaxibacumabA monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage moderate to severe plaque psoriasis and active psoriatic arthritis or ankylosing spondylitis.
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
MetreleptinA leptin analogue used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Asfotase alfaAn enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
Peginterferon beta-1aAn interferon beta used to treat relapsing forms of multiple sclerosis.
Protamine sulfateA blood factor used when the reversal of the anticoagulant effect of heparin is necessary and for the treatment of heparin overdose.
IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
EvolocumabA PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis.
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
CaseinAn extract from Casein used in allergy testing.
ThioredoxinThioredoxin is a small dithiol protein and specific reductant for major allergenic proteins present in foods from animal and plant products. It is a 12-kD oxidoreductase enzyme encoded by TXN...
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Antithrombin III humanAn alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
Human varicella-zoster immune globulinA solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
ConatumumabConatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
BremelanotideBremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of...
TabalumabTabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
FiclatuzumabFiclatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
FigitumumabFigitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
SetmelanotideSetmelanotide is indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
OnartuzumabOnartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
TremelimumabTremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DalotuzumabDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
LigelizumabAn IgE-directed monoclonal antibody under investigation for the treatment of chronic spontaneous urticaria (CSU).
SeribantumabSeribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
RomosozumabA monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
CrenezumabCrenezumab has been used in trials studying the treatment of Alzheimer's Disease.
RilotumumabRilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
AnifrolumabA monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus.
OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
GantenerumabA fully human IgG1κ monoclonal antibody with specificity for amyloid-beta oligomers and fibrils under investigation for the treatment of Alzheimer's disease.
VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
PatritumabPatritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
FulranumabFulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
TarextumabTarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
SotaterceptSotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.
GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
DuligotuzumabDuligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
TralokinumabA monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.
EtrolizumabA humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease.
GanitumabGanitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Polatuzumab vedotinA CD79b antibody conjugate indicated to treat relapsed or refractory B-cell lymphoma.
InclacumabInclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
CixutumumabCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
AscrinvacumabAscrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
AducanumabA monoclonal antibody indicated in the treatment of Alzheimer's disease.
TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
DusigitumabDusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
FresolimumabFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
Mirvetuximab SoravtansineMirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
InebilizumabA humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
MavrilimumabMavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
BimagrumabBimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
TovetumabTovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
IbalizumabA CD4-specific antibody used to treat HIV infections.
IntetumumabIntetumumab has been used in trials studying the treatment of Melanoma.
CarlumabCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Naptumomab estafenatoxNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
CrotedumabCrotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
DepatuxizumabDepatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
AmatuximabAmatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
RobatumumabRobatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
RacotumomabRacotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
OlokizumabA humanized anti-IL-6 IgG4κ antibody under investigation for use in autoimmune conditions including rheumatoid arthritis.
EdrecolomabNot Annotated
NebacumabNot Annotated
Human cytomegalovirus immune globulinA solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
SemaglutideA glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus.
SulesomabMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
BesilesomabA monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
ErenumabA calcitonin-gene related peptide antagonist used to prevent migraines.
FremanezumabA humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
FanolesomabAn anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
Moxetumomab pasudotoxA CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
ElapegademaseA recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency.
LebrikizumabLebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
BenralizumabA monoclonal antibody used to treat eosinophilic asthma.
ZalutumumabZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
PlozalizumabPlozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
SifalimumabSifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
EmapalumabAn interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
Turoctocog alfa pegolTuroctocog alfa pegol is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to...
Polymyxin BA polymyxin antibiotic used to treat a wide variety of infections in the body.
GirentuximabInvestigated for use/treatment in gall bladder cancer and renal cell carcinoma.
RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
Anetumab ravtansineAnetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
IsatuximabA chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
IcrucumabIcrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
EmactuzumabEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
PamrevlumabPamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
Human interferon betaA polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS).
ApomabApomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
AbrilumabAbrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
UtomilumabUtomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
ZolbetuximabZolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
SuvratoxumabSuvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
MitazalimabMitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
BleselumabBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
IstiratumabIstiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
GMA-161GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Tucotuzumab celmoleukinTucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous...
Ladiratuzumab vedotinLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
TomaralimabTomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
VesencumabVesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
Lulizumab pegolLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Lorukafusp alfaLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Naratuximab emtansineNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
CT-011Investigated for use/treatment in cancer/tumors (unspecified).
SonepcizumabInvestigated for use/treatment in solid tumors.
Thrombin alfaA platelet activating factor used to treat minor bleeding.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
Depatuxizumab mafodotinNo approved indication.
UblituximabA low-fucose monoclonal anti-CD20 antibody with enhanced ADCC being investigated for use in leukemia, lymphoma, and autoimmune conditions such as multiple sclerosis.
Vadastuximab talirineVadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
VarlilumabVarlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
UrelumabUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
FasinumabA monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia in patients requiring regular red blood cell transfusions.
GS-5745GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
VanucizumabVanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Labetuzumab govitecanLabetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
EnsituximabEnsituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
FezakinumabFezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
Indusatumab vedotinIndusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
PegvaliaseAn enzyme used to treat phenylketonuria in patients with phenylalanine levels that are too high on current treatment.
BimekizumabAn anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
Rovalpituzumab tesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
NamilumabNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
BezlotoxumabA monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
TisagenlecleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
BurosumabA fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
EptinezumabA monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
LecanemabLecanemab is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease.
CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
TagraxofuspA CD123-directed cytotoxin used to treat plasmacytoid dendritic cell neoplasm.
CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
SetrusumabSetrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
XentuzumabXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
ParsatuzumabParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
RozanolixizumabRozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
OpicinumabOpicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
MargetuximabAn Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
GremubamabGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
TafasitamabA CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
FrovocimabFrovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
TezepelumabA human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe asthma.
Telisotuzumab vedotinTelisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
GedivumabGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Sofituzumab vedotinSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
EvinacumabA monoclonal antibody targeted against angiopoetin-like protein 3 (ANGPTL3) used as an adjunct with other lipid-lowering therapies for the treatment of homozygous familiar hypercholesterolemia.
ZenocutuzumabZenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
InolimomabInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry...
TheralizumabTheralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia...
Belantamab mafodotinAn anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
PentaglobinPentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched...
Agalsidase alfaA recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide.
AbagovomabAbagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
Dapirolizumab pegolDapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
EfungumabEfungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
ForalumabForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Indatuximab ravtansineIndatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
ItolizumabItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
MagrolimabMagrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
OlinvacimabOlinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
OntuxizumabOntuxizumab is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and Clinical Evaluation).
OtlertuzumabOtlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Anti-SARS-CoV-2 immunoglobulinHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains...
Silver proteinateA nasal decongestant and antiseptic of the nasal and ear canals.
ActoxumabActoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
ToralizumabToralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
BirtamimabBirtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
VolagidemabVolagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
FibrinNot Annotated
Antilymphocyte immunoglobulin (horse)A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Tetanus immune globulin, humanA solution of antibodies used to prevent tetanus after an injury.
Digoxin Immune Fab (Ovine)An antibody binding fragment which binds digoxin molecules which is used as an antidote to digoxin overdose.
Anthrax immune globulin humanAn immunizing agent used for the treatment of inhalational anthrax in adult and pediatric patients in combination with antibacterial agents.
BermekimabBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
CrizanlizumabA monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
SatralizumabA subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
OdesivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
MaftivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
AtoltivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
BamlanivimabA neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
AnsuvimabA fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease.
Human Rho(D) immune globulinA solution of antibodies used to prevent isoimmunization of Rho(D) negative patients exposed to Rho(D) positive blood in pregnancy or transfusion.
BentracimabBentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).
Cantuzumab ravtansineInvestigated for use/treatment in gastric cancer.
Cergutuzumab amunaleukinCergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).
GosuranemabGosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
Lifastuzumab vedotinLifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Trastuzumab duocarmazineTrastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Vorsetuzumab mafodotinVorsetuzumab mafodotin is under investigation in clinical trial NCT01677390 (A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma).
AnrukinzumabAnrukinzumab has been used in trials studying the diagnostic of Asthma.
BemarituzumabBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
BrontictuzumabBrontictuzumab has been used in trials studying the treatment of Adenoid Cystic Carcinoma, Relapsed or Refractory Solid Tumors, and Relapsed or Refractory Lymphoid Malignancies.
CabiralizumabCabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
CusatuzumabA CD70-directed monoclonal antibody under investigation for the treatment of hematological malignancies.
DezamizumabDezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
DomagrozumabDomagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers.
EnoblituzumabEnoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).
FaricimabAn IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema.
FlotetuzumabFlotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).
ImgatuzumabImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
LacnotuzumabLacnotuzumab is under investigation in clinical trial NCT01643850 (MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)).
LutikizumabLutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
MirikizumabMirikizumab is under investigation in clinical trial NCT03053622 (A Study of Mirikizumab (LY3074828) Injection in Healthy Participants).
MonalizumabMonalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
MosunetuzumabMosunetuzumab is under investigation in clinical trial NCT03677154 (A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in...
OlendalizumabOlendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
OzoralizumabOzoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis.
PascolizumabInvestigated for use/treatment in asthma.
VonlerolizumabVonlerolizumab is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who...
PrasinezumabPrasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
QuilizumabQuilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).
RavagalimabRavagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis...
RuplizumabInvestigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
SamalizumabSamalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
SpartalizumabSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
TalacotuzumabTalacotuzumab is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
TefibazumabTefibazumab is under investigation in clinical trial NCT00198289 (Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs).
TelisotuzumabTelisotuzumab is under investigation in clinical trial NCT01472016 (Study of ABT-700 in Subjects With Advanced Solid Tumors).
TibulizumabTibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).
TislelizumabTislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
TomuzotuximabTomuzotuximab is under investigation in clinical trial NCT02052960 (CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer).
VatelizumabVatelizumab has been used in trials studying the treatment of Ulcerative Colitis.
VopratelimabVopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
VunakizumabVunakizumab is under investigation in clinical trial NCT03463187 (Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis).
AmivantamabAn EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
PlasminogenPlasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
SotrovimabA monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
RegdanvimabA monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
ImdevimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
CasirivimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
CilgavimabAn extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
TixagevimabAn extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
Protein hydrolysateNot Annotated
OrdesekimabOrdesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
CetrorelixA synthetic peptide antagonist of gonadotropin releasing hormone used to prevent luteinizing hormone surges in women undergoing assisted reproduction therapy.
CitrullineUsed for nutritional supplementation, also for treating dietary shortage or imbalance.
PerflutrenA diagnostic medication to improve contrast during echocardiograms.
GonadorelinA synthetic GnRH used to test the function of gonadotropes and the pituitary.
LucinactantIntended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
REV131Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts.
CR665Investigated for use/treatment in pain (acute or chronic).
Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
Contulakin-GInvestigated for use/treatment in pain (acute or chronic).
IcatibantA bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
LabradimilInvestigated for use/treatment in brain cancer and pediatric indications.
TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
BuserelinA LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females.
GanirelixA GnRH antagonist used in assisted reproduction in women undergoing controlled ovarian hyperstimulation to control ovulation by inhibiting the premature LH surges.
HistrelinA GnRH agonist found in subcutaneous implants used for the treatment of pediatric patients with central precocious puberty and the palliative treatment of advanced prostate cancer.
VonapanitaseVonapanitase is under investigation for the treatment of Chronic Kidney Disease.
BombesinBombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and...
UlinastatinUlinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
BradykininBradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.
SelepressinSelepressin has been used in trials studying the treatment of Septic Shock.
TecemotideTecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
AviscumineCy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
Zoptarelin doxorubicinZoptarelin doxorubicin has been used in trials studying the treatment of Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, and Urothelial Carcinoma, among others.
Plasma protein fraction (human)A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures.
PRM-151PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
EflapegrastimEflapegrastim is under investigation in clinical trial NCT02953340 (Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide...
RemtolumabRemtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
HemoglobinAn iron-containing protein found in all red blood cells (RBCs) for proper binding of oxygen and transport throughout the body, included in blood transfusions in severe hemorrhage.
Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Interferon alfa-2aA form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses.
OprelvekinA form of recombinant interleukin-11 used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
Interferon beta-1aA form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis.
Interferon alfacon-1A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
FelypressinFor use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.
Interferon alfa-2bA form of recombinant human interferon used to treat hepatitis B and C infection, genital warts, hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDs-related Kaposi's sarcoma.
NafarelinA gonadotropin releasing hormone agonist used to treat central precocious puberty.
ColistinA polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.
Aminolevulinic acidA porphyrin precursor used to treat actinic keratosis of the face, scalp, and upper extremities, as well as to visualize a glioma.
ColistimethateAn antibiotic indicated for treatment of infections caused by susceptible strains of certain gram-negative bacilli. It is particularly useful for targeting sensitive strains of Pseudomonas aeruginosa.
PaclitaxelA taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.
PramlintideAn amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
GalsulfaseA recombinant human enzyme used as replacement enzyme therapy for the treatment of of adults and children with Mucopolysaccharidosis VI, a rare genetic disorder caused by a deficiency of a lysosomal enzyme.
AbataceptA disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
TetracosactideA diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.
CorticotropinA diagnostic agent used in the screening of patients presumed to have adrenocortical insufficiency.
ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
Bacteriochlorophyll AA specific bacteriochlorophyll that is similar in structure to CHLOROPHYLL A.
TerlipressinA drug used to treat bleeding caused by esophageal varices.
VapreotideFor the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
NesiritideA recombinant natriuretic peptide used for the treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
ThymalfasinIndicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate...
G17DTIntended for the treatment of various forms of cancer.
DirucotideFor the treatment of multiple sclerosis (MS).
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
TigapotideFor the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
AbaloparatideA parathyroid hormone-related protein (PTHrP) analog used for the treatment of osteoporosis in postmenopausal women with a high risk of fracture.
LeptinInvestigated for use/treatment in lipodystrophy and obesity.
TopsalysinInvestigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
ElafinInvestigated for use/treatment in inflammatory disorders (unspecified).
Interferon alfaAn immunomodulator used to treat hepatitis B and C as well as certain types of cancer including cutaneous T-cell lymphoma and renal cell carcinoma.
GlatiramerAn immunomodulator used to reduce the frequency of relapses in Multiple Sclerosis (MS).
Keyhole limpet hemocyaninInvestigated for use/treatment in bladder cancer and solid tumors.
Cintredekin besudotoxInvestigated for use/treatment in brain cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
Ciliary neurotrophic factorInvestigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
CorticorelinA synthetic corticotropin-releasing factor analog used to diagnose causes of excessive adrenocorticotropic hormone (ACTH) production.
TifuvirtideInvestigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
PraconaseInvestigated for use/treatment in spinal cord injuries.
Fibroblast growth factor-1Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
IRX-2Investigated for use/treatment in cancer/tumors (unspecified), head and neck cancer, and solid tumors.
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
Sar9, Met (O2)11-Substance PInvestigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
CTCE-0214Investigated for use/treatment in adverse effects (chemotherapy), blood (blood forming organ disorders, unspecified), cancer/tumors (unspecified), neutropenics, and vascular diseases.
GI-5005Investigated for use/treatment in hepatitis (viral, C).
IRL-1620Investigated for use/treatment in cancer/tumors (unspecified).
Nelipepimut-SInvestigated for use/treatment in prostate cancer and breast cancer.
TraferminInvestigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
LanoteplaseInvestigated for use/treatment in myocardial infarction.
AviptadilNot Annotated
OtilimabInvestigated for use/treatment in inflammatory disorders (unspecified).
AZX-100Investigated for use/treatment in scar tissue.
RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
Calcitonin gene-related peptideInvestigated for use/treatment in myocardial infarction, heart disease, and asthma.
AtaciceptInvestigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
VitespenInvestigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.
EndostatinInvestigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
RepiferminInvestigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease.
VelaferminInvestigated for use/treatment in adverse effects (chemotherapy).
OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
AMGN-0007Investigated for use/treatment in osteoporosis and bone metastases.
ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
AtibuclimabInvestigated for use/treatment in sepsis and septicemia and pneumonia.
EmfilerminInvestigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
BaminerceptInvestigated for use/treatment in rheumatoid arthritis.
OmigananInvestigated for use/treatment in bacterial infection and rosacea.
PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DiaPep 277Investigated for use/treatment in diabetes mellitus type 1, autoimmune diseases, and diabetes mellitus type 2.
PasireotideA somatostatin analog used in the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery is not appropriate.
AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
BelataceptA selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
LanreotideA somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly.
TriptorelinA GnRH agonist indicated for the palliative treatment of advanced prostate cancer.
DADLEA delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.
DPDPEA heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
TesamorelinA growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.
AfliberceptA vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
GlucarpidaseA carboxypeptidase enzyme used to reduce plasma concentrations of methotrexate in patients with impaired renal function.
Corticorelin ovine triflutateA synthetic corticotropin-releasing hormone used for diagnostic purposes in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
SomatostatinA natural peptide hormone used to treat acute bleeding from esophageal varices, gastrointestinal ulcers, and gastritis; prevent pancreatic complications after surgery; and restrict secretions of the upper intestine, pancreas, and biliary tract.
AncestimA human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection.
Methoxy polyethylene glycol-epoetin betaA synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Turoctocog alfaAn antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
Chorionic Gonadotropin (Human)A naturally-occurring hormone produced during human placenta used for the treatment of prepubertal cryptorchidism and hypogonadotropic hypogonadism in selected males, and induction of pregnancy in selected infertile women.
PolaprezincPeptic ulcer disease, dyspepsia .
Fibrinogen humanA hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Conestat alfaA recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
Antihemophilic factor (recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...
Technetium Tc-99m nofetumomab merpentanTc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer. The small cell lung cancer is a syndrome characterized by the...
Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic...
ProtirelinA synthetic analogue of thyrotropin-releasing hormone that has been used during diagnostic tests to evaluate function of the thyroid gland.
Secretin humanA secretin hormone used to stimulate pancreatic or gastric secretions to diagnose exocrine pancreas dysfunction, gastrinoma, and abnormalities in the bile and pancreatic ducts.
Human papillomavirus type 16 L1 capsid protein antigenHuman papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is...
Bordetella pertussis pertactin antigenBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .
DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Iron protein succinylateNot Annotated
GelatinGelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also...
ThrombinA coagulation factor used to stop bleeding during surgery.
ProthrombinA coagulation factor used for emergency reversal of vitamin K antagonist therapy.
Factor IX Complex (Human)A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.
DeslorelinDeslorelin acetate is an injectable gonadotropin releasing hormone super-agonist also known as an LHRH agonist. It stops the production of sex hormones.
Epoetin deltaEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Eptotermin alfaA bone morphogenetic protein that is widely expressed during EMBRYONIC DEVELOPMENT. It is both a potent osteogenic factor and a specific regulator of nephrogenesis. Eptotermin alfa is an ingredient in...
Dibotermin alfaindicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. indicated for single-level...
Rusalatide acetateChrysalin has been used in trials studying the treatment of Radius Fracture.
CarnosineCarnosine has been investigated for the treatment of Gulf War Illness.
Angiotensin 1-7TXA127 has been investigated for the treatment of Miscellaneous Peripheral Blood Cell Abnormalities.
EndostarEndostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Neuropeptide YNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
Indium In-111 pentetreotideIndium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
Angiotensin IIA peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock.
TesidolumabTesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.
AvoterminJuvista has been investigated for the treatment, prevention, and basic science of Scars, Keloid, and Cicatrix.
TAK-448TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.
Interleukin-7Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.
Thymosin beta-4Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
UlocuplumabUlocuplumab is under investigation in Solid Tumor.
TrebananibTrebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon...
NagrestipenNagrestipen has been used in trials studying the treatment of CANCER, Neoplasm, Metastasis, Radiation Oncology, and Neoplasm Metastasis.
TT-232Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).
Vanutide cridificarVanutide cridificar has been investigated for the treatment of Alzheimer Disease.
BinetrakinBinetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
Tetulomab tetraxetan Lu-177Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
Abicipar PegolAbicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.
BlisibimodBlisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
DulanerminDulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
FletikumabFletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).
Vatreptacog alfaVatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
MuplestimMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
ConberceptConbercept has been investigated for the basic science of Age-related Macular Degeneration.
MolgramostimMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
PentetreotideA somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours.
SpriferminSprifermin has been used in trials studying the treatment of Osteoarthritis, Knee and Cartilage Injury of Knee.
Nerve Growth FactorNerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.
AclerastideAclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.
NavicixizumabNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Endothelin-1Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
FirategrastFirategrast has been used in trials studying the treatment of Multiple Sclerosis.
TiplimotideTiplimotide has been used in trials studying the treatment of Multiple Sclerosis.
SomatoprimSomatoprim is under investigation for the treatment of Acromegaly.
Pancreatic PolypeptidePancreatic Polypeptide has been investigated for the treatment of Diabetes Mellitus, Type 1.
Olipudase alfaOlipudase alfa has been used in trials studying the treatment of Sphingomyelin Lipidosis and Human Acid Sphingomyelinase Deficiency.
Interleukin-10Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
Factor XIII (human)A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency.
IsoxaflutoleBalance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
AlbusomatropinAlbusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency.
Von Willebrand factor humanA blood clotting factor used to manage bleeding episodes in von Willebrand disease and hemophilia A,.
LenograstimA granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors.
Coagulation factor X humanA coagulation factor used to treat Factor X deficiency to control bleeding.
Coagulation factor VII humanA coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia.
Anti-inhibitor coagulant complexA medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B.
Coagulation Factor IX HumanA coagulation factor used to treat hemophilia B or factor IX hemophilia.
Cerliponase alfaAn enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Antihemophilic factor humanA Factor VIII replacement therapy used to treat hemophilia A.
KallidinogenaseNot Annotated
LipegfilgrastimA medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
Trenonacog alfaHuman coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.
AlsactideNot Annotated
SulglicotideNot Annotated
OrnipressinNot Annotated
SaruplaseNot Annotated
ProtamineA heparin antagonist indicated in the treatment of heparin overdoses, to counteract heparins preoperatively, or during cardiac surgery and dialysis.
ElcatoninNot Annotated
Hemoglobin crosfumarilHemoglobin in which the alpha-subunit are cross-linked intramolecularly.
Albutrepenonacog alfaA recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
CenegerminA recombinant human nerve growth factor used to treat neurotrophic keratitis.
Nonacog beta pegolA recombinant coagulation Factor IX derivative used to treat hemophilia B.
Moroctocog alfaA recombinant Factor VIII used to treat hemophilia A to control bleeding.
Interleukin-1 alpha, human recombinantNot Annotated
Basic Fibroblast Growth FactorBasic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
NepiderminNot Annotated
Insulin-like growth factor IIThe insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth...
Beroctocog alfaBeroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in...
Andexanet alfaA recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban.
LypressinNot Annotated
Prezatide copperCommonly used in cosmetic products for the skin and hair .
Peginterferon lambda-1aPeginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).
VofatamabVofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
ProcalcitoninProcalcitonin is under investigation in clinical trial NCT03440060 (Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD).
OsocimabOsocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).
Human interleukin-2Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
UteroglobinUteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).
SelicrelumabSelicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
SutimlimabA monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease.
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
ToripalimabToripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
Melanoma antigen recognized by T-cells 1Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery).
AnfibatideAnfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
Interferon alfa-2cInterferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).
BempegaldesleukinBempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib...
LenzilumabLenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
PegilodecakinPegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).
TirzepatideA dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise.
alpha-Lactalbuminalpha-Lactalbumin is under investigation in clinical trial NCT02082418 (Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly).
Gastric inhibitory polypeptideGastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
AvidinAvidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
IscalimabIscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
FutuximabFutuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).
EdratideEdratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
Marzeptacog alfa (activated)Marzeptacog alfa (activated) is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
GimsilumabGimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
TebentafuspA bispecific gp100 peptide-HLA-directed CD3 T cell engager used to treat unresectable or metastatic uveal melanoma.
OntamalimabOntamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
BevifimodBevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
OrilanolimabOrilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
DAS-181DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).
Vocimagene amiretrorepvecVocimagene amiretrorepvec is under investigation in clinical trial NCT02576665 (A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca...
PegbelferminPegbelfermin is under investigation in clinical trial NCT03486899 (A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis).
SOR-C13SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
ALT-801ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
TeceleukinTeceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).
Coagulation factor XIaCoagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).
ElgemtumabElgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Onasemnogene abeparvovecA gene therapy used to treat neonatal and infant patients with spinal muscular atrophy caused by bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Silk sericinNot Annotated
PadeliporfinA vascular-acting photosensitizer used to treat low-risk prostate cancer in adults.
SpesolimabSpesolimab is under investigation in clinical trial NCT03886246 (A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130).
Edodekin alfaEdodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or...
TemelimabTemelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
ZilucoplanZilucoplan is under investigation in clinical trial NCT04225871 (Open-label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis).
Moderna COVID-19 VaccineAn mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, in patients aged 18 years and older.
Anti-SARS-CoV-2 REGN-COV2Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
BNT162b1 SARS-CoV-2 VaccineBNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding...
Pfizer-BioNTech COVID-19 VaccineAn mRNA vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus.
Brexucabtagene autoleucelA modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
Alunacedase alfaAlunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Viral Macrophage-Inflammatory ProteinViral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer...
Interferon KappaInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it...
SintilimabNot Annotated
EnvafolimabNot Annotated
AZD7442AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
XAV-19XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a...
EtesevimabEtesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...
Rurioctocog alfa pegolA pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A.
IsegananIseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
AldaferminAldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Nonalcoholic Steatohepatitis...
Bizalimogene ralaplasmidBizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade...
DopastatinDopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).
DynorphinDynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).
VEGFR2-169VEGFR2-169 is under investigation in clinical trial NCT00655785 (Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)).
GlenzocimabNot Annotated
GontivimabGontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
ItepekimabItepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
Kisspeptin-10Kisspeptin-10 is under investigation in clinical trial NCT03771326 (KP-10 and Insulin Secretion in Men).
Loncastuximab tesirineAn antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
NirsevimabNirsevimab is under investigation in clinical trial NCT03959488 (A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(rsv) Lower Respiratory Track Infection (LRTI)...
Parathyroid Hormone-Related Protein 1-36Parathyroid Hormone-Related Protein 1-36 is under investigation in clinical trial NCT00853723 (Comparison Study of Pthrp and PTH to Treat Osteoporosis).
Pegylated Recombinant Human Arginase IPegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).
PexigananPexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).
RibaxamaseRibaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).
GlofitamabGlofitamab is under investigation in clinical trial NCT04408638 (A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants...
FelzartamabFelzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
AstegolimabAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
LevilimabLevilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
AxatilimabAxatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
ZansecimabZansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
AvdoralimabAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Efineptakin alfaEfineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more...
PidacmeranPidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
BNT-162A1BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
VilobelimabVilobelimab is under investigation in clinical trial NCT03895801 (Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis).
NarsoplimabAn anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
EpiVacCoronaEpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus . It is currently...
MeplazumabMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Pam2csk4Not Available
InbakiceptNot Available
Collagen-polyvinylpyrrolidoneCollagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation . It is characterized by antifibrotic, fibrolytic, and immunomodulatory properties...
Dialyzable leukocyte extractTransferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator. It is thought to have widespread effects on the immune system, and effective...
LactoferrinLactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
Succinylated gelatinA plasma volume expander indicated alone or in combination with blood transfusions.
AmlintideA medication used in combination with corticosteroids for the treatment of hemorrhoids.
Efanesoctocog alfaEfanesoctocog alfa is under investigation in clinical trial NCT04759131 (Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A).
Idecabtagene vicleucelAn autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
IanalumabIanalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
BudigalimabBudigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...
AbelacimabAbelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
ReltecimodReltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
TengonerminTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
Corynebacterium diphtheriae CRM197 proteinNot Annotated
LirentelimabLirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
EnibarcimabEnibarcimab is under investigation in clinical trial NCT03989531 (Adrecizumab in Cardiogenic Shock).
Tisotumab vedotinA tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
BebtelovimabA human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
Drugs & Drug Targets
DrugTargetType
LepirudinProthrombintarget
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
Dornase alfaDNAtarget
Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
Denileukin diftitoxCytokine receptor common subunit gammatarget
Denileukin diftitoxInterleukin-2 receptor subunit betatarget
EtanerceptTumor necrosis factortarget
EtanerceptLymphotoxin-alphatarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
EtanerceptComplement component 1q (C1q)target
LeuprolideGonadotropin-releasing hormone receptortarget
Peginterferon alfa-2aInterferon alpha/beta receptor 2target
Peginterferon alfa-2aInterferon alpha/beta receptor 1target
Peginterferon alfa-2aCytochrome P450 1A2enzyme
AlteplaseUrokinase plasminogen activator surface receptortarget
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogentarget
AlteplasePlasminogen activator inhibitor 1target
Interferon alfa-n1Interferon alpha/beta receptor 2target
Interferon alfa-n1Interferon alpha/beta receptor 1target
Interferon alfa-n1Cytochrome P450 1A2enzyme
Darbepoetin alfaErythropoietin receptortarget
UrokinaseUrokinase plasminogen activator surface receptortarget
UrokinasePlasminogentarget
UrokinasePlasminogen activator inhibitor 2target
UrokinasePlasminogen activator inhibitor 1target
UrokinasePlasma serine protease inhibitortarget
UrokinaseNidogen-1target
UrokinaseLow-density lipoprotein receptor-related protein 2target
UrokinaseSuppressor of tumorigenicity 14 proteintarget
UrokinaseMacrophage metalloelastaseenzyme
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogentarget
ReteplasePlasminogen activator inhibitor 1target
ErythropoietinErythropoietin receptortarget
Salmon calcitoninCalcitonin receptortarget
Interferon alfa-n3Interferon alpha/beta receptor 1target
Interferon alfa-n3Interferon alpha/beta receptor 2target
Interferon alfa-n3Cytochrome P450 1A2enzyme
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
SargramostimBone marrow proteoglycantarget
SargramostimInterleukin-3 receptor subunit alphatarget
SargramostimCytokine receptor common subunit betatarget
SargramostimSyndecan-2target
Peginterferon alfa-2bInterferon alpha/beta receptor 1target
Peginterferon alfa-2bInterferon alpha/beta receptor 2target
Peginterferon alfa-2bCytochrome P450 1A2enzyme
Peginterferon alfa-2bCytochrome P450 2D6enzyme
Peginterferon alfa-2bCytochrome P450 2C9enzyme
Antihemophilic factor, human recombinantCoagulation factor Xtarget
Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
Antihemophilic factor, human recombinantCoagulation factor IXtarget
Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
Antihemophilic factor, human recombinantCalreticulintarget
Antihemophilic factor, human recombinantCalnexintarget
Antihemophilic factor, human recombinantProtein ERGIC-53target
Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
Antihemophilic factor, human recombinantvon Willebrand factortarget
Antihemophilic factor, human recombinantProthrombinenzyme
Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
AnakinraInterleukin-1 receptor type 1target
Gramicidin DP-glycoprotein 1transporter
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor Itarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-atarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor IBtarget
Human immunoglobulin GComplement C3target
Human immunoglobulin GComplement C4-Atarget
Human immunoglobulin GComplement C4-Btarget
Human immunoglobulin GComplement C5target
Interferon gamma-1bInterferon gamma receptor 1target
Interferon gamma-1bInterferon gamma receptor 2target
Interferon gamma-1bCytochrome P450 1A2enzyme
DesmopressinVasopressin V1a receptortarget
DesmopressinVasopressin V1b receptortarget
DesmopressinVasopressin V2 receptortarget
DesmopressinProstaglandin G/H synthase 1enzyme
DesmopressinProstaglandin G/H synthase 2enzyme
Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
Coagulation factor VIIa Recombinant HumanTissue factortarget
Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
PaliferminFibroblast growth factor receptor 2target
PaliferminFibroblast growth factor receptor 1target
PaliferminBasement membrane-specific heparan sulfate proteoglycan core proteintarget
GlucagonGlucagon receptortarget
GlucagonGlucagon-like peptide 2 receptortarget
GlucagonGlucagon-like peptide 1 receptortarget
AldesleukinInterleukin-2 receptor subunit betatarget
AldesleukinInterleukin-2 receptor subunit alphatarget
AldesleukinCytokine receptor common subunit gammatarget
AldesleukinProstaglandin G/H synthase 2enzyme
AldesleukinCytosolic phospholipase A2enzyme
AldesleukinCytochrome P450 3A4enzyme
AldesleukinXanthine dehydrogenase/oxidaseenzyme
AldesleukinCytochrome P450 2E1enzyme
Botulinum toxin type BVesicle-associated membrane protein 1target
Botulinum toxin type BVesicle-associated membrane protein 2target
Botulinum toxin type BSynaptotagmin-2target
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
AdalimumabTumor necrosis factortarget
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
AbciximabVitronectintarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
Albumin humanNitric oxidetarget
InfliximabTumor necrosis factortarget
FollitropinFollicle-stimulating hormone receptortarget
VasopressinVasopressin V1a receptortarget
VasopressinVasopressin V2 receptortarget
VasopressinVasopressin V1b receptortarget
VasopressinCanalicular multispecific organic anion transporter 1transporter
VasopressinOxytocin receptortarget
Interferon beta-1bInterferon alpha/beta receptor 1target
Interferon beta-1bInterferon alpha/beta receptor 2target
Interferon beta-1bCytochrome P450 1A2enzyme
Insulin porkInsulin receptortarget
Insulin porkInsulin-like growth factor 1 receptortarget
Insulin porkCytochrome P450 1A2enzyme
Insulin porkInsulin-degrading enzymeenzyme
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
RituximabB-lymphocyte antigen CD20target
BasiliximabInterleukin-2 receptor subunit alphatarget
BasiliximabInterleukin-2 receptor subunit betatarget
MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
MuromonabT-cell surface glycoprotein CD3 delta chaintarget
MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
Ibritumomab tiuxetanB-lymphocyte antigen CD20target
TositumomabB-lymphocyte antigen CD20target
TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
Botulinum toxin type ASynaptosomal-associated protein 25target
Botulinum toxin type ARho-related GTP-binding protein RhoBtarget
Botulinum toxin type ASerum albumincarrier
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Capromab pendetideGlutamate carboxypeptidase 2target
EfalizumabIntegrin alpha-Ltarget
EfalizumabIntegrin alpha-Xtarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
FilgrastimGranulocyte colony-stimulating factor receptortarget
FilgrastimNeutrophil elastaseenzyme
BecaplerminPlatelet-derived growth factor receptor betatarget
BecaplerminAlpha-2-macroglobulintarget
BecaplerminPlatelet-derived growth factor receptor alphatarget
Agalsidase betaGlobotriaosylceramidetarget
Agalsidase betaCation-dependent mannose-6-phosphate receptortransporter
NatalizumabIntegrin alpha-4target
NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
NatalizumabIntercellular adhesion molecule 1target
EnfuvirtideEnvelope glycoproteintarget
EnfuvirtideCytochrome P450 2C19enzyme
EnfuvirtideCytochrome P450 2E1enzyme
PalivizumabFusion glycoprotein F0target
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
PalivizumabComplement C1r subcomponenttarget
PalivizumabComplement C1q subcomponent subunit Atarget
PalivizumabComplement C1q subcomponent subunit Btarget
PalivizumabComplement C1q subcomponent subunit Ctarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
PentagastrinGastrin/cholecystokinin type B receptortarget
PentagastrinCholinesteraseenzyme
EculizumabComplement C5target
PanitumumabEpidermal growth factor receptortarget
RanibizumabVascular endothelial growth factor Atarget
MecaserminInsulin-like growth factor 1 receptortarget
MecaserminInsulin-like growth factor-binding protein 3target
MecaserminInsulin receptortarget
MecaserminCation-independent mannose-6-phosphate receptortarget
MecaserminInsulin-like growth factor-binding protein 3carrier
MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
MecaserminInsulin-like growth factor-binding protein 1carrier
MecaserminInsulin-like growth factor-binding protein 2carrier
MecaserminInsulin-like growth factor-binding protein 4carrier
MecaserminInsulin-like growth factor-binding protein 5carrier
MecaserminInsulin-like growth factor-binding protein 6carrier
Insulin glulisineInsulin receptortarget
Insulin glulisineInsulin-like growth factor 1 receptortarget
Insulin glulisineCytochrome P450 1A2enzyme
GaliximabT-lymphocyte activation antigen CD80target
AfamelanotideMelanocyte-stimulating hormone receptortarget
AfelimomabTumor necrosis factortarget
EpratuzumabB-cell receptor CD22target
OregovomabMucin-16target
IGN311Epidermal growth factor receptortarget
IGN311Receptor tyrosine-protein kinase erbB-2target
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
MatuzumabEpidermal growth factor receptortarget
FontolizumabInterferon gammatarget
CR002Platelet-derived growth factor Dtarget
RozrolimupabRhesus blood group D antigentarget
Hepatitis B immune globulinHBsAgtarget
Oportuzumab monatoxEpithelial cell adhesion moleculetarget
BriakinumabInterleukin-12 subunit betatarget
BriakinumabInterleukin-23 subunit alphatarget
RamucirumabVascular endothelial growth factor receptor 2target
FarletuzumabFolate receptor alphatarget
UstekinumabInterleukin-12 subunit betatarget
UstekinumabInterleukin-23target
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
PRO-542Free fatty acid receptor 4target
TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
RI 624Beta-nerve growth factortarget
MYO-029Growth/differentiation factor 8target
LeronlimabC-C chemokine receptor type 5target
Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
OlaratumabPlatelet-derived growth factor receptor alphatarget
TB-402Coagulation factor VIIItarget
Caplacizumabvon Willebrand factortarget
IMC-1C11Vascular endothelial growth factor receptor 1target
IMC-1C11Vascular endothelial growth factor receptor 2target
IMC-1C11Vascular endothelial growth factor receptor 3target
EldelumabC-X-C motif chemokine 10target
LumiliximabLow affinity immunoglobulin epsilon Fc receptortarget
CanakinumabInterleukin-1 betatarget
IpilimumabCytotoxic T-lymphocyte protein 4target
ClenoliximabT-cell surface glycoprotein CD4target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
ElotuzumabSLAM family member 7target
AVE9633Myeloid cell surface antigen CD33target
AVE9633Cytochrome P450 3A4enzyme
CarotuximabEndoglintarget
XmAb 2513Tumor necrosis factor receptor superfamily member 8target
Coltuximab ravtansineB-lymphocyte antigen CD19target
Coltuximab ravtansineCytochrome P450 3A4enzyme
TeprotumumabInsulin-like growth factor 1 receptortarget
LucatumumabTumor necrosis factor receptor superfamily member 5target
PertuzumabReceptor tyrosine-protein kinase erbB-2target
SiplizumabT-cell surface antigen CD2target
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
SibrotuzumabSeprasetarget
BivatuzumabCD44 antigentarget
LexatumumabTumor necrosis factor receptor superfamily member 10Btarget
ReslizumabInterleukin-5target
TeplizumabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabEpithelial cell adhesion moleculetarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
MepolizumabInterleukin-5target
DenosumabTumor necrosis factor ligand superfamily member 11target
OfatumumabB-lymphocyte antigen CD20target
LiraglutideGlucagon-like peptide 1 receptortarget
LiraglutideDipeptidyl peptidase 4enzyme
LiraglutideNeprilysinenzyme
LiraglutideSerum albumincarrier
GolimumabTumor necrosis factortarget
AprotininTrypsin-1target
AprotininChymotrypsinogen Btarget
AprotininPlasminogentarget
AprotininKallikrein-1target
AprotininCholinesteraseenzyme
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
BelimumabTumor necrosis factor ligand superfamily member 13Btarget
RaxibacumabProtective antigentarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
ObinutuzumabB-lymphocyte antigen CD20target
SecukinumabInterleukin-17Atarget
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
NivolumabProgrammed cell death protein 1target
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
PembrolizumabProgrammed cell death protein 1target
DulaglutideGlucagon-like peptide 1 receptortarget
MetreleptinLeptin receptortarget
BlinatumomabB-lymphocyte antigen CD19target
BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DinutuximabGD2 disialogangliosidetarget
Asfotase alfaPyrophosphatetarget
Peginterferon beta-1aCytochrome P450 1A2enzyme
Peginterferon beta-1aInterferon alpha/beta receptor 1target
Protamine sulfateCoagulation factor Xtarget
Protamine sulfateAntithrombin-IIItarget
AlirocumabProprotein convertase subtilisin/kexin type 9target
EvolocumabProprotein convertase subtilisin/kexin type 9target
DaratumumabADP-ribosyl cyclase 1target
NecitumumabEpidermal growth factor receptortarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
IxekizumabInterleukin-17Atarget
AtezolizumabProgrammed cell death 1 ligand 1target
Antithrombin III humanAntithrombin-IIItarget
BremelanotideMelanocyte-stimulating hormone receptortarget
BremelanotideMelanocortin receptor 4target
BremelanotideMelanocortin receptor 3target
BremelanotideMelanocortin receptor 5target
BremelanotideAdrenocorticotropic hormone receptortarget
SetmelanotideMelanocortin receptor 4target
DurvalumabProgrammed cell death 1 ligand 1target
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
TremelimumabCytotoxic T-lymphocyte protein 4target
GuselkumabInterleukin-23 subunit alphatarget
LigelizumabImmunoglobulin heavy constant epsilontarget
RomosozumabSclerostintarget
AvelumabProgrammed cell death 1 ligand 1target
AnifrolumabInterferon alpha/beta receptor 1target
OcrelizumabB-lymphocyte antigen CD20target
GantenerumabAmyloid beta A4 proteintarget
Lorvotuzumab mertansineCytochrome P450 3A4enzyme
SotaterceptActivin receptor type-2Atarget
GevokizumabInterleukin-1 betatarget
DupilumabInterleukin-4 receptor subunit alphatarget
DupilumabInterleukin-13target
DupilumabInterleukin-4target
TralokinumabInterleukin-13target
EtrolizumabIntegrin beta-7target
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
CixutumumabInsulin-like growth factor 1 receptortarget
AducanumabAmyloid beta A4 proteintarget
Mirvetuximab SoravtansineCytochrome P450 3A4enzyme
MogamulizumabC-C chemokine receptor type 4target
InebilizumabB-lymphocyte antigen CD19target
DacetuzumabTumor necrosis factor receptor superfamily member 5target
IbalizumabT-cell surface glycoprotein CD4target
IbalizumabC-C chemokine receptor type 5target
IbalizumabC-X-C chemokine receptor type 4target
AmatuximabMesothelintarget
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
OlokizumabInterleukin-6target
EmicizumabCoagulation factor IXtarget
EmicizumabCoagulation factor Xtarget
SemaglutideSerum albumincarrier
SemaglutideDipeptidyl peptidase 4enzyme
SemaglutideNeprilysinenzyme
SemaglutideGlucagon-like peptide 1 receptortarget
SemaglutideLipoprotein lipaseenzyme
SemaglutideAlpha-amylase 1enzyme
BesilesomabCarcinoembryonic antigentarget
TildrakizumabInterleukin-23target
TildrakizumabCytochrome P450 4A11enzyme
ErenumabCalcitonin gene-related peptide type 1 receptortarget
FremanezumabCalcitonin gene-related peptide 1target
FremanezumabCalcitonin gene-related peptide 2target
LanadelumabPlasma kallikreintarget
Moxetumomab pasudotoxB-cell receptor CD22target
Moxetumomab pasudotoxElongation factor 2target
ElapegademaseAdenosinetarget
LebrikizumabInterleukin-13target
LebrikizumabIL13 proteintarget
BenralizumabInterleukin-5 receptor subunit alphatarget
BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
ZalutumumabEpidermal growth factor receptortarget
PlozalizumabC-C chemokine receptor type 2target
SifalimumabInterferon alpha-2target
EmapalumabInterferon gammatarget
Turoctocog alfa pegolVitamin K-dependent protein Cenzyme
Turoctocog alfa pegolCoagulation factor Xenzyme
Turoctocog alfa pegolCoagulation factor IXtarget
Turoctocog alfa pegolCoagulation factor Xtarget
Turoctocog alfa pegolProthrombintarget
Turoctocog alfa pegolvon Willebrand factortarget
Polymyxin BBacterial outer membranetarget
Polymyxin BSolute carrier family 15 member 2transporter
GirentuximabCarbonic anhydrase 9target
GirentuximabInterleukin-2target
RisankizumabInterleukin-23target
IsatuximabADP-ribosyl cyclase 1target
Human interferon betaCytochrome P450 1A2enzyme
Human interferon betaInterferon alpha/beta receptor 1target
Human interferon betaSerum albumincarrier
CT-011Programmed cell death protein 1target
Thrombin alfaCoagulation factor VIIItarget
Thrombin alfaCoagulation factor Vtarget
Thrombin alfaFibrinogen alpha chaintarget
Thrombin alfaFibrinogen beta chaintarget
Thrombin alfaFibrinogen gamma chaintarget
RavulizumabComplement C5target
Depatuxizumab mafodotinEpidermal growth factor receptortarget
Depatuxizumab mafodotinTubulin beta chaintarget
UblituximabB-lymphocyte antigen CD20target
UrelumabTumor necrosis factor receptor superfamily member 9target
FasinumabBeta-nerve growth factortarget
BimekizumabInterleukin-17Atarget
BimekizumabInterleukin-17Ftarget
BezlotoxumabClostridium difficile Toxin Btarget
TisagenlecleucelB-lymphocyte antigen CD19target
BurosumabFibroblast growth factor 23target
EptinezumabCalcitonin gene-related peptide 1target
EptinezumabCalcitonin gene-related peptide 2target
GalcanezumabCalcitonin gene-related peptide 1target
GalcanezumabCalcitonin gene-related peptide 2target
CemiplimabProgrammed cell death protein 1target
TagraxofuspInterleukin-3 receptor subunit alphatarget
TagraxofuspADP-ribosylation factor-like protein 2target
CamrelizumabProgrammed cell death protein 1target
BrolucizumabVascular endothelial growth factor Atarget
Trastuzumab deruxtecanP-glycoprotein 1transporter
Trastuzumab deruxtecanHigh affinity immunoglobulin gamma Fc receptor Itarget
Trastuzumab deruxtecanDNA topoisomerase 1target
Trastuzumab deruxtecanLysosomal alpha-glucosidaseenzyme
Trastuzumab deruxtecanDNA topoisomerase 1enzyme
Trastuzumab deruxtecanCathepsin Benzyme
Trastuzumab deruxtecanCathepsin L1enzyme
Trastuzumab deruxtecanCytochrome P450 3A4enzyme
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B1transporter
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B3transporter
Trastuzumab deruxtecanMultidrug and toxin extrusion protein 2transporter
Trastuzumab deruxtecanMultidrug resistance-associated protein 1transporter
Trastuzumab deruxtecanATP-binding cassette sub-family G member 2transporter
MargetuximabReceptor tyrosine-protein kinase erbB-2target
TafasitamabB-lymphocyte antigen CD19target
TezepelumabThymic stromal lymphopoietintarget
EvinacumabAngiopoietin-related protein 3target
InolimomabInterleukin-2 receptor subunit alphatarget
Belantamab mafodotinSolute carrier organic anion transporter family member 1B1transporter
Belantamab mafodotinSolute carrier organic anion transporter family member 1B3transporter
Belantamab mafodotinMultidrug resistance-associated protein 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 2transporter
Belantamab mafodotinBile salt export pumptransporter
Belantamab mafodotinP-glycoprotein 1transporter
Belantamab mafodotinTumor necrosis factor receptor superfamily member 17target
Agalsidase alfaCation-dependent mannose-6-phosphate receptortransporter
Agalsidase alfaGlobotriaosylceramidetarget
OlinvacimabVascular endothelial growth factor receptor 2target
OtlertuzumabLeukocyte antigen CD37target
Tetanus immune globulin, humanTetanus toxintarget
Digoxin Immune Fab (Ovine)Digoxintarget
Anthrax immune globulin humanProtective antigentarget
CrizanlizumabP-selectintarget
Enfortumab vedotinCytochrome P450 3A4enzyme
Enfortumab vedotinNectin-4target
Enfortumab vedotinP-glycoprotein 1transporter
SatralizumabInterleukin-6 receptor subunit alphatarget
OdesivimabEnvelope glycoproteintarget
MaftivimabEnvelope glycoproteintarget
AtoltivimabEnvelope glycoproteintarget
BamlanivimabSpike glycoproteintarget
NaxitamabGD2 disialogangliosidetarget
AnsuvimabEnvelope glycoproteintarget
Human Rho(D) immune globulinRhesus blood group D antigentarget
CusatuzumabCD70 antigentarget
DostarlimabProgrammed cell death protein 1target
FaricimabVascular endothelial growth factor Atarget
FaricimabAngiopoietin-2target
PascolizumabInterleukin-4target
RuplizumabCD40 ligandtarget
SpartalizumabProgrammed cell death protein 1target
TislelizumabProgrammed cell death protein 1target
AmivantamabEpidermal growth factor receptortarget
AmivantamabHepatocyte growth factor receptortarget
AmivantamabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PlasminogenTissue-type plasminogen activatorenzyme
PlasminogenUrokinase-type plasminogen activatorenzyme
SotrovimabSpike glycoproteintarget
RegdanvimabSpike glycoproteintarget
ImdevimabSpike glycoproteintarget
CasirivimabSpike glycoproteintarget
CilgavimabSpike glycoproteintarget
TixagevimabSpike glycoproteintarget
CetrorelixLutropin-choriogonadotropic hormone receptortarget
CetrorelixGonadotropin-releasing hormone receptortarget
CitrullineNitric oxide synthase, endothelialtarget
CitrullineArgininosuccinate synthasetarget
CitrullineN(G),N(G)-dimethylarginine dimethylaminohydrolase 2target
CitrullineArgininosuccinate synthetase, isoform CRA_atarget
CitrullineN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
CitrullineOrnithine carbamoyltransferase, mitochondrialtarget
CitrullineNitric oxide synthase, braintarget
CitrullineNitric oxide synthase, inducibletarget
CitrullineProtein-arginine deiminase type-4target
CitrullineProtein-arginine deiminase type-6target
CitrullineProtein-arginine deiminase type-1target
CitrullineProtein-arginine deiminase type-3target
CitrullineProtein-arginine deiminase type-2target
CitrullineSolute carrier family 22 member 6transporter
GonadorelinGonadotropin-releasing hormone receptortarget
GonadorelinPutative gonadotropin-releasing hormone II receptortarget
REV131Histamine H4 receptortarget
CR665Kappa-type opioid receptortarget
Albinterferon Alfa-2BCytochrome P450 1A2enzyme
LJP 1082Beta-2-glycoprotein 1target
Contulakin-GVoltage-dependent N-type calcium channel subunit alpha-1Btarget
IcatibantB2 bradykinin receptortarget
IcatibantAminopeptidase Ntarget
LabradimilB2 bradykinin receptortarget
TG4010Mucin-1target
TG4010Interleukin-2target
BuserelinLutropin-choriogonadotropic hormone receptortarget
BuserelinGonadotropin-releasing hormone receptortarget
BuserelinCytochrome P450 19A1enzyme
GanirelixGonadotropin-releasing hormone receptortarget
HistrelinGonadotropin-releasing hormone receptortarget
Protein S humanCoagulation factor Vtarget
Protein S humanCoagulation factor Xtarget
Protein S humanVitamin K-dependent protein Ctarget
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogentarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseTetranectintarget
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseCalreticulintarget
TenecteplaseCalnexintarget
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
TenecteplasePlasminogentarget
Interferon alfa-2aInterferon alpha/beta receptor 1target
Interferon alfa-2aInterferon alpha/beta receptor 2target
Interferon alfa-2aCytochrome P450 1A2enzyme
OprelvekinInterleukin-11 receptor subunit alphatarget
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
Interferon beta-1aInterferon alpha/beta receptor 1target
Interferon beta-1aInterferon alpha/beta receptor 2target
Interferon beta-1aCytochrome P450 1A2enzyme
Interferon alfacon-1Interferon alpha/beta receptor 1target
Interferon alfacon-1Interferon alpha/beta receptor 2target
Interferon alfacon-1Cytochrome P450 1A2enzyme
StreptokinasePlasminogentarget
StreptokinaseProteinase-activated receptor 1target
StreptokinaseCytosolic phospholipase A2enzyme
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
FelypressinVasopressin V1a receptortarget
Interferon alfa-2bInterferon alpha/beta receptor 2target
Interferon alfa-2bInterferon alpha/beta receptor 1target
Interferon alfa-2bCytochrome P450 1A2enzyme
NafarelinGonadotropin-releasing hormone receptortarget
NafarelinPutative gonadotropin-releasing hormone II receptortarget
ColistinBacterial outer membranetarget
Aminolevulinic acidDelta-aminolevulinic acid dehydratasetarget
Aminolevulinic acidSolute carrier family 15 member 1transporter
Aminolevulinic acidSolute carrier family 15 member 2transporter
ColistimethateBacterial outer membranetarget
PaclitaxelApoptosis regulator Bcl-2target
PaclitaxelTubulin beta-1 chaintarget
PaclitaxelCytochrome P450 2C8enzyme
PaclitaxelCytochrome P450 3A4enzyme
PaclitaxelCytochrome P450 3A5enzyme
PaclitaxelCytochrome P450 3A7enzyme
PaclitaxelBile salt export pumptransporter
PaclitaxelP-glycoprotein 1transporter
PaclitaxelMultidrug resistance-associated protein 1transporter
PaclitaxelMultidrug resistance-associated protein 7transporter
PaclitaxelCytochrome P450 19A1enzyme
PaclitaxelCytochrome P450 1B1enzyme
PaclitaxelSolute carrier organic anion transporter family member 1B3transporter
PaclitaxelNuclear receptor subfamily 1 group I member 2target
PaclitaxelMicrotubule-associated protein 4target
PaclitaxelMicrotubule-associated protein 2target
PaclitaxelMicrotubule-associated protein tautarget
PaclitaxelCanalicular multispecific organic anion transporter 1transporter
PramlintideReceptor activity-modifying protein 1target
PramlintideReceptor activity-modifying protein 2target
PramlintideReceptor activity-modifying protein 3target
PramlintideCalcitonin receptortarget
GalsulfasePerilipin-3target
GalsulfaseDermatan sulfatetarget
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AbataceptCytotoxic T-lymphocyte protein 4target
TetracosactideAdrenocorticotropic hormone receptortarget
CorticotropinAdrenocorticotropic hormone receptortarget
CorticotropinCorticoliberintarget
Corticotropin3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
Corticotropin25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
Corticotropin1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
CorticotropinCytochrome P450 3A4enzyme
Bacteriochlorophyll ABacteriochlorophyll a proteintarget
Bacteriochlorophyll ABacteriochlorophyll a proteintarget
TerlipressinVasopressin V1a receptortarget
TerlipressinVasopressin V2 receptortarget
TerlipressinVasopressin V1b receptortarget
VapreotideNeurokinin 1 receptortarget
VapreotideSomatostatin receptor type 2target
VapreotideSomatostatin receptor type 5target
VapreotideCytochrome P450 3A4enzyme
NesiritideAtrial natriuretic peptide receptor 1target
NesiritideAtrial natriuretic peptide receptor 2target
NesiritideAtrial natriuretic peptide receptor 3target
DesmoteplasePlasminogentarget
Tigapotide40S ribosomal protein SAtarget
AbaloparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
LeptinLeptin receptortarget
ElafinNeutrophil elastasetarget
ElafinMyeloblastintarget
ElafinMyeloperoxidaseenzyme
Interferon alfaInterferon alpha/beta receptor 1target
Interferon alfaCytochrome P450 1A2enzyme
GlatiramerHLA class II histocompatibility antigen, DRB1-1 beta chaintarget
GlatiramerHLA class II histocompatibility antigen, DRB1-15 beta chaintarget
GlatiramerHLA class II histocompatibility antigen, DRB1-4 beta chaintarget
Keyhole limpet hemocyaninInterleukin-2target
Cintredekin besudotoxInterleukin-13target
RomiplostimThrombopoietin receptortarget
RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
RegramostimGM-CSF receptor alpha subunittarget
RegramostimCholinesteraseenzyme
CorticorelinDopamine beta-hydroxylaseenzyme
TifuvirtidePlasma serine protease inhibitortarget
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
Sar9, Met (O2)11-Substance PCytochrome P450 19A1enzyme
Sar9, Met (O2)11-Substance PCholinesteraseenzyme
Sar9, Met (O2)11-Substance PProstaglandin G/H synthase 2enzyme
PegdinetanibVascular endothelial growth factor receptor 2target
CTCE-0214Stromal cell-derived factor 1target
IRL-1620Endothelin B receptortarget
Nelipepimut-SHLA class I histocompatibility antigen, A-2 alpha chaintarget
Nelipepimut-SHLA class I histocompatibility antigen, A-3 alpha chaintarget
LanoteplaseUrokinase plasminogen activator surface receptortarget
LanoteplaseFibrinogen alpha chaintarget
LanoteplaseKallikrein-1target
LanoteplaseLaminin subunit alpha-5target
LanoteplaseCoagulation factor Xtarget
LanoteplaseFibronectintarget
LanoteplasePlasminogen activator inhibitor 2target
LanoteplaseTetranectintarget
LanoteplaseKeratin, type II cytoskeletal 8target
LanoteplaseAnnexin A2target
LanoteplaseLaminin subunit beta-1target
LanoteplaseLaminin subunit gamma-1target
LanoteplaseLaminin subunit alpha-1target
LanoteplaseCalreticulintarget
LanoteplaseCalnexintarget
LanoteplaseProlow-density lipoprotein receptor-related protein 1target
LanoteplaseLaminin subunit alpha-3target
RilonaceptInterleukin-1 betatarget
RilonaceptInterleukin-1 alphatarget
RilonaceptInterleukin-1 receptor antagonist proteintarget
Endostatin72 kDa type IV collagenasetarget
EndostatinMatrix metalloproteinase-9target
EndostatinCollagenase 3target
EndostatinFocal adhesion kinase 1target
EndostatinE-selectintarget
EndostatinCytochrome P450 19A1enzyme
OnerceptTumor necrosis factortarget
AMGN-0007Tumor necrosis factor ligand superfamily member 11target
ThrombopoietinThrombopoietin receptortarget
AtibuclimabMonocyte differentiation antigen CD14target
PasireotideSomatostatin receptor type 1target
PasireotideSomatostatin receptor type 2target
PasireotideSomatostatin receptor type 3target
PasireotideSomatostatin receptor type 5target
PasireotideCytochrome P450 3A4enzyme
BelataceptT-lymphocyte activation antigen CD86target
BelataceptT-lymphocyte activation antigen CD80target
LanreotideSomatostatin receptor type 2target
LanreotideSomatostatin receptor type 5target
LanreotideCytochrome P450 3A4enzyme
TriptorelinGonadotropin-releasing hormone receptortarget
DADLESolute carrier organic anion transporter family member 1B1transporter
DPDPESolute carrier organic anion transporter family member 1B3transporter
TesamorelinGrowth hormone-releasing hormone receptortarget
AfliberceptVascular endothelial growth factor Atarget
AfliberceptPlacenta growth factortarget
AfliberceptVascular endothelial growth factor Btarget
Corticorelin ovine triflutateCorticotropin-releasing factor receptor 1target
SomatostatinSomatostatin receptor type 1target
SomatostatinSomatostatin receptor type 2target
SomatostatinSomatostatin receptor type 3target
SomatostatinSomatostatin receptor type 4target
SomatostatinSomatostatin receptor type 5target
SomatostatinP-glycoprotein 1transporter
SomatostatinCytochrome P450 3A4enzyme
AncestimMast/stem cell growth factor receptor Kittarget
Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
Turoctocog alfaCoagulation factor IXtarget
Turoctocog alfaCoagulation factor Xtarget
Turoctocog alfaProthrombintarget
Chorionic Gonadotropin (Human)Lutropin-choriogonadotropic hormone receptortarget
PolaprezincTumor necrosis factortarget
PolaprezincInterleukin-6target
PolaprezincInterleukin-3target
PolaprezincSuperoxide dismutase [Cu-Zn]enzyme
PolaprezincHeme oxygenase 1enzyme
PolaprezincSuperoxide dismutase [Mn], mitochondrialenzyme
PolaprezincGlutathione S-transferase theta-1enzyme
PolaprezincGlutathione peroxidase 1enzyme
PolaprezincPeroxiredoxin-1enzyme
PolaprezincPeroxiredoxin-5, mitochondrialenzyme
PolaprezincVascular endothelial growth factor receptor 1target
PolaprezincBeta-nerve growth factortarget
PolaprezincPlatelet-derived growth factor receptor betatarget
PolaprezincHeat shock protein HSP 90-alphatarget
PolaprezincHeat shock protein HSP 90-betatarget
Conestat alfaComplement C1r subcomponenttarget
Conestat alfaComplement C1s subcomponenttarget
Conestat alfaPlasma kallikreintarget
Conestat alfaCoagulation factor XIItarget
Conestat alfaProthrombintarget
Conestat alfaCoagulation factor XItarget
Conestat alfaTissue-type plasminogen activatortarget
Antihemophilic factor (recombinant), PEGylatedvon Willebrand factortarget
Antihemophilic factor (recombinant), PEGylatedvon Willebrand factorcarrier
Technetium Tc-99m nofetumomab merpentanEpithelial cell adhesion moleculetarget
Technetium Tc-99m nofetumomab merpentanB-lymphocyte antigen CD20target
ProtirelinThyrotropin Releasing Hormone Receptortarget
Secretin humanSecretin receptortarget
DesirudinCarboxypeptidase A1enzyme
ThrombinProteinase-activated receptor 1target
ThrombinProteinase-activated receptor 4target
ThrombinCoagulation factor XItarget
ThrombinCoagulation factor XIII A chaintarget
ThrombinCoagulation factor XIII B chaintarget
ThrombinFibrinogen alpha chaintarget
ThrombinFibrinogen beta chaintarget
ThrombinFibrinogen gamma chaintarget
ThrombinCoagulation factor Vtarget
ThrombinCoagulation factor VIIItarget
ProthrombinFibrinogen alpha chaintarget
ProthrombinFibrinogen beta chaintarget
ProthrombinCoagulation factor XIII A chaintarget
ProthrombinCarboxypeptidase B2target
ProthrombinCoagulation factor Xenzyme
Dibotermin alfaBone morphogenetic protein receptor type-1Atarget
Dibotermin alfaBone morphogenetic protein receptor type-2target
Angiotensin IIType-1 angiotensin II receptortarget
Von Willebrand factor humanCoagulation factor VIIItarget
Von Willebrand factor humanCollagen alpha-1(I) chaintarget
Von Willebrand factor humanA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
Von Willebrand factor humanAsialoglycoprotein receptor 1target
Von Willebrand factor humanProlow-density lipoprotein receptor-related protein 1target
LenograstimGranulocyte colony-stimulating factor receptortarget
Coagulation factor VII humanTissue factortarget
Coagulation factor VII humanCoagulation factor Xtarget
Coagulation factor VII humanCoagulation factor IXtarget
Anti-inhibitor coagulant complexCoagulation factor Xtarget
Anti-inhibitor coagulant complexProthrombintarget
Anti-inhibitor coagulant complexFibrinogen alpha chaintarget
Anti-inhibitor coagulant complexFibrinogen beta chaintarget
Anti-inhibitor coagulant complexCoagulation factor XIII A chaintarget
Anti-inhibitor coagulant complexCoagulation factor Vtarget
Anti-inhibitor coagulant complexCoagulation factor VIIItarget
Anti-inhibitor coagulant complexCoagulation factor VIItarget
Coagulation Factor IX HumanCoagulation factor Xtarget
Coagulation Factor IX HumanCoagulation factor XItarget
Coagulation Factor IX HumanCoagulation factor VIItarget
Coagulation Factor IX HumanCoagulation factor VIIItarget
Coagulation Factor IX HumanProthrombintarget
Coagulation Factor IX HumanProlow-density lipoprotein receptor-related protein 1target
Coagulation Factor IX HumanVitamin K-dependent gamma-carboxylasetarget
Cerliponase alfaCation-independent mannose-6-phosphate receptortarget
Antihemophilic factor humanCoagulation factor IXtarget
Antihemophilic factor humanCoagulation factor Xtarget
Antihemophilic factor humanVitamin K-dependent protein Cenzyme
LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
Albutrepenonacog alfaCoagulation factor Xtarget
Albutrepenonacog alfaCoagulation factor VIIIenzyme
CenegerminHigh affinity nerve growth factor receptortarget
Nonacog beta pegolCoagulation factor VIItarget
Nonacog beta pegolCoagulation factor VIIItarget
Nonacog beta pegolCoagulation factor Xtarget
Moroctocog alfaCoagulation factor Xtarget
Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
Moroctocog alfaCoagulation factor IXtarget
Moroctocog alfaAsialoglycoprotein receptor 2target
Moroctocog alfa78 kDa glucose-regulated proteintarget
Moroctocog alfaCalreticulintarget
Moroctocog alfaCalnexintarget
Moroctocog alfaProtein ERGIC-53target
Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
Moroctocog alfaMultiple coagulation factor deficiency protein 2target
Moroctocog alfavon Willebrand factortarget
Moroctocog alfaProthrombinenzyme
Moroctocog alfaVitamin K-dependent protein Cenzyme
Andexanet alfaTissue factor pathway inhibitortarget
LypressinVasopressin V1a receptortarget
LypressinVasopressin V2 receptortarget
LypressinVasopressin V1b receptortarget
LypressinCanalicular multispecific organic anion transporter 1transporter
SutimlimabComplement C1s subcomponenttarget
ToripalimabProgrammed cell death protein 1target
Interferon alfa-2cCytochrome P450 1A2enzyme
TirzepatideGlucagon-like peptide 1 receptortarget
TirzepatideGastric inhibitory polypeptidetarget
TirzepatideSerum albumincarrier
TebentafuspMelanocyte protein PMELtarget
PadeliporfinSolute carrier organic anion transporter family member 1B1transporter
PadeliporfinSolute carrier organic anion transporter family member 1B3transporter
PadeliporfinSerum albumincarrier
Anti-SARS-CoV-2 REGN-COV2Spike glycoproteintarget
Brexucabtagene autoleucelB-lymphocyte antigen CD19target
SintilimabProgrammed cell death protein 1target
EnvafolimabProgrammed cell death 1 ligand 1target
EtesevimabSpike glycoproteintarget
Rurioctocog alfa pegolvon Willebrand factortarget
Rurioctocog alfa pegolCoagulation factor VIIItarget
Loncastuximab tesirineB-lymphocyte antigen CD19target
Loncastuximab tesirineP-glycoprotein 1transporter
Loncastuximab tesirineCytochrome P450 3A4enzyme
Loncastuximab tesirineCytochrome P450 3A5enzyme
VilobelimabComplement C5target
NarsoplimabMannan-binding lectin serine protease 2target
Pam2csk4Toll-like receptor 6target
Pam2csk4Toll-like receptor 2target
Idecabtagene vicleucelTumor necrosis factor receptor superfamily member 17target
Tisotumab vedotinCytochrome P450 3A4enzyme
Tisotumab vedotinTissue factortarget
Tisotumab vedotinP-glycoprotein 1transporter
BebtelovimabSpike glycoproteintarget